Preclinical Models of Attention Deficit Hyperactivity Disorder: Neurobiology, Drug Discovery, and Beyond.

IF 2.7 3区医学 Q2 PSYCHIATRY

Journal of Attention Disorders Pub Date : 2024-03-01 Epub Date: 2023-12-12 DOI:10.1177/10870547231215286

Deirdre M McCarthy, Thomas J Spencer, Pradeep G Bhide

{"title":"Preclinical Models of Attention Deficit Hyperactivity Disorder: Neurobiology, Drug Discovery, and Beyond.","authors":"Deirdre M McCarthy, Thomas J Spencer, Pradeep G Bhide","doi":"10.1177/10870547231215286","DOIUrl":null,"url":null,"abstract":"Objective: We offer an overview of ADHD research using mouse models of nicotine exposure.Method: Nicotine exposure of C57BL/6 or Swiss Webster mice occurred during prenatal period only or during the prenatal and the pre-weaning periods. Behavioral, neuroanatomical and neurotransmitter assays were used to investigate neurobiological mechanisms of ADHD and discover candidate ADHD medications.Results: Our studies show that norbinaltorphimine, a selective kappa opioid receptor antagonist is a candidate novel non-stimulant ADHD treatment and that a combination of methylphenidate and naltrexone has abuse deterrent potential with therapeutic benefits for ADHD. Other studies showed transgenerational transmission of ADHD-associated behavioral traits and demonstrated that interactions between untreated ADHD and repeated mild traumatic brain injury produced behavioral traits not associated with either condition alone.Conclusion: Preclinical models contribute to novel insights into ADHD neurobiology and are valuable tools for drug discovery and translation to benefit humans with ADHD.","PeriodicalId":15237,"journal":{"name":"Journal of Attention Disorders","volume":" ","pages":"880-894"},"PeriodicalIF":2.7000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Attention Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10870547231215286","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We offer an overview of ADHD research using mouse models of nicotine exposure.

Method: Nicotine exposure of C57BL/6 or Swiss Webster mice occurred during prenatal period only or during the prenatal and the pre-weaning periods. Behavioral, neuroanatomical and neurotransmitter assays were used to investigate neurobiological mechanisms of ADHD and discover candidate ADHD medications.

Results: Our studies show that norbinaltorphimine, a selective kappa opioid receptor antagonist is a candidate novel non-stimulant ADHD treatment and that a combination of methylphenidate and naltrexone has abuse deterrent potential with therapeutic benefits for ADHD. Other studies showed transgenerational transmission of ADHD-associated behavioral traits and demonstrated that interactions between untreated ADHD and repeated mild traumatic brain injury produced behavioral traits not associated with either condition alone.

Conclusion: Preclinical models contribute to novel insights into ADHD neurobiology and are valuable tools for drug discovery and translation to benefit humans with ADHD.

查看原文本刊更多论文

注意缺陷多动障碍的临床前模型：神经生物学、药物发现及其他》。

目的：概述利用尼古丁暴露小鼠模型进行的多动症研究：我们概述了利用尼古丁暴露小鼠模型进行的多动症研究：方法：C57BL/6或瑞士韦伯斯特小鼠仅在产前或在产前和断奶前暴露于尼古丁。方法：C57BL/6或瑞士韦伯斯特小鼠仅在出生前或在出生前和断奶前暴露于尼古丁，通过行为、神经解剖和神经递质测定来研究多动症的神经生物学机制，并发现多动症的候选药物：我们的研究表明，选择性卡巴阿片受体拮抗剂诺比纳托啡是一种候选的新型非兴奋剂多动症治疗药物，哌醋甲酯和纳曲酮的组合具有抑制滥用的潜力，对多动症有治疗作用。其他研究表明，与多动症相关的行为特征会代代相传，并证明未经治疗的多动症与反复轻度脑外伤之间的相互作用会产生与其中任何一种情况无关的行为特征：临床前模型有助于深入了解多动症的神经生物学，是药物发现和转化的宝贵工具，可造福于多动症患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Attention Disorders PSYCHIATRY-

CiteScore

7.60

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Journal of Attention Disorders (JAD) focuses on basic and applied science concerning attention and related functions in children, adolescents, and adults. JAD publishes articles on diagnosis, comorbidity, neuropsychological functioning, psychopharmacology, and psychosocial issues. The journal also addresses practice, policy, and theory, as well as review articles, commentaries, in-depth analyses, empirical research articles, and case presentations or program evaluations.